Clinical trials: Carcinoma of Lung
Lung Neoplasms, Small Cell Lung Cancer
Molecular Profiling in Small Cell Lung Cancer
This protocol is to obtain tumor tissues and blood samples from patients with a confirmed histological diagnosis of Small cell lung cancer(SCLC) for molecular profiling.
- Trial name
- MPSCLC (NCT03162705)
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Zhujiang Hospital
EGFR-TKI-resistant Non-small Cell Lung Cancer With Leptomeningeal Metastasis
Safety and Efficacy of Intrathecal Sacituzumab Tirumotecan for Leptomeningeal Metastasis in EGFR-TKI-Resistant Non-Small Cell Lung Cancer
This study is a Phase I, single-arm, single-center, dose-escalation clinical trial designed to investigate the safety and efficacy of intrathecal injection of sacituzumab tirumotecan (sac-TMT) in patients with EGFR…
- Trial name
- NCT07702305
- Testing
- Sacituzumab tirumotecan
- Volunteers
- 15 people
- Sponsor
- Henan Cancer Hospital
Brain Metastases from Non-small Cell Lung Cancer
Durvalumab (MEDI4736) and Radiosurgery (fSRT Vs. PULSAR) for the Treatment of Non-Small Cell Lung Cancer Brain Metastases
This is a research study to find out if the new anti-cancer drug Durvalumab combined with radiation therapy to the brain will work in treating brain metastases from non-small cell lung cancer (NSCLC).
- Trial name
- NCT04889066
- Testing
- Stereotactic Radiation Therapy, Durvalumab
- Sponsor
- University of Texas Southwestern Medical Center
Lung Cancer
Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00066222
- Testing
- Cisplatin, Etoposide, Radiation therapy
- Where
- 104 sites in United States
- Volunteers
- 72 people
- Sponsor
- Radiation Therapy Oncology Group
Lung Cancer
Screening for Lung Cancer in Subjects With Family History of Lung Cancer
Lung cancer can be detected via screening of high-risk individuals, i.e current or ex-heavy smokers, with low-dose computer tomography (LDCT) of thorax.
- Trial name
- NCT05762731
- Testing
- Low dose CT thorax
- Where
- Hong Kong
- Volunteers
- 1,520 people
- Sponsor
- The University of Hong Kong
Fatigue, Self Efficacy
Understanding the Post-Surgical Non-Small Cell Lung Cancer Patient's Symptom Experience
Among 13 core symptoms across 3,106 breast, colorectal, prostate, and lung cancer patients, persons with lung cancer were the most symptomatic, with moderate to severe fatigue being reported with the greatest prevalence.
- Conditions
- Fatigue, Self Efficacy, Quality of Life, Physical Activity
- Trial name
- NCT03724331
- Testing
- Light Physical Activity 1, Light Physical Activity 2, Support Education Activity
- Where
- United States
- Volunteers
- 235 people
- Sponsor
- University of Nebraska
Carcinoma, Non-Small-Cell Lung
Study Of Use Of Pemetrexed In Patients With Non-Small Lung Cancer Metastatic In Andalusian Public Health System
STUDY OF USE OF PEMETREXED IN PATIENTS WITH NON-SMALL LUNG CANCER METASTATIC IN ANDALUSIAN PUBLIC HEALTH SYSTEM
- Trial name
- NCT01877902
- Where
- 18 sites in Spain
- Volunteers
- 190 people
- Sponsor
- Fundación Pública Andaluza Progreso y Salud
Non Small Cell Lung Cancer
LIQUIK: LIQUId Biopsy for Detection of Actionable Genomic BiomarKers in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
To explore the non-inferiority of a cfDNA amplicon-based liquid biopsy technology vs. standard of care tissue biopsy-based NGS in detecting guideline- recommended biomarkers in patients with metastatic non-squamous Non-small Cell…
- Trial name
- LIQUIK (NCT04703153)
- Where
- 5 sites in United States
- Volunteers
- 151 people
- Sponsor
- Lucence Health Inc.
Small Cell Lung Cancer Extensive Stage
Application of ctDNA in the Evaluation of Curative Effect and Prognosis of SCLC Patients
The purpose of this study is to evaluate the application value of circulating tumor DNA(ctDNA) with efficacy evaluation and prognostic assessment in patients with unresectable SCLC, who were receiving radiotherapy and…
- Trial name
- NCT05066945
- Testing
- Observation
- Volunteers
- 40 people
- Sponsor
- Xiangya Hospital of Central South University
Lung Cancer, Surgery
CMR Right Ventricular Contractile Reserve Following Lung Resection
Feasibility study investigating CMR dobutamine stress testing before and after lung resection
- Conditions
- Lung Cancer, Surgery, Anesthesia
- Trial name
- NCT06465277
- Testing
- Dobutamine stress CMR, Cardiac biomarker sample
- Where
- United Kingdom
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Belfast Health and Social Care Trust
Neoplasms
A Study of Carboplatin + Paclitaxel and MK0683 in Patients With Chemotherapy-naive Non-Small Cell Lung Cancer (NSCLC)(0683-066)
The clinical study will evaluate safety, tolerability and Pharmacokinetics of MK0683 in combination with carboplatin and paclitaxel in chemotherapy-naive NSCLC patients.
- Trial name
- NCT00424775
- Testing
- MK0683, vorinostat
- Volunteers
- 3 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer Patients
Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance (PIONeeR-BioMarkers (BM) Profiling)
PIONeeR study is a prospective, multicenter study without administration of an investigational product. The promotion and funding will be done by the Assistance Publique Hôpitaux de Marseille (APHM), the coordination by AMU.
- Trial name
- PIONeeR (NCT03493581)
- Testing
- BIOPSY, blood-sampled, feces samples
- Where
- France
- Volunteers
- 450 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Advanced Solid Tumors, Merkel Cell Carcinoma
A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma
To determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and recommended Phase 2 dose (RP2D) of FF-10850 (topotecan liposome injection) in patients with advanced solid tumors including…
- Trial name
- NCT04047251
- Testing
- FF-10850 Topotecan Liposome Injection
- Where
- 7 sites in United States
- Volunteers
- 96 people
- Sponsor
- Fujifilm Pharmaceuticals U.S.A., Inc.
Lung Neoplasm Malignant, Resectable Lung Non-Small Cell Carcinoma
Prognostic Value of the 6-minute Stepper Test in Non-small Cell Lung Cancer Surgery
The objective of this study is to evaluate the performances of the Six-Minute Stepper Test (6MST) and Sit To Stand test (STST) to predict post-operative complications after minimally invasive lung cancer resection.
- Trial name
- PREOTEST (NCT03824977)
- Testing
- Six minutes stepper test (6MST), Sit to stand test (STST)
- Where
- France
- Volunteers
- 122 people
- Sponsor
- University Hospital, Rouen
Non-small Cell Lung Cancer (NSCLC)
An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement
ROS1 is a receptor tyrosine kinase with constitutive kinase activity. ROS1 was previously discovered in cell lines where ROS1 fused with other proteins to act as a driver oncogene.
- Trial name
- NCT01964157
- Testing
- LDK378
- Where
- South Korea
- Volunteers
- 32 people
- Sponsor
- Yonsei University
Lung Cancer
Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and pemetrexed disodium, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00234052
- Testing
- bevacizumab, carboplatin, pemetrexed
- Where
- 5 sites in United States
- Volunteers
- 51 people
- Sponsor
- Northwestern University
Progression Free Survival
Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer
Acquired epidermal growth factor receptor (EGFR) T790M mutation is the most common genetic change after resistant to first generation EGFR tyrosine kinase inhibitor (EGFR TKI) in non-small cell lung cancer.
- Trial name
- NCT02959749
- Testing
- Osimertinib, docetaxel, bevacizumab
- Where
- China
- Volunteers
- 147 people
- Sponsor
- Qingdao Central Hospital
Lung Cancer (NSCLC)
Perioperative and Postoperative Circulating Tumor Cell Monitoring in Different Stage of NSCLC
The study aims to enroll 500 non-small cell lung cancer patients at various stages and to employ this technology for CTC detection, with subsequent cytomorphological and chromosomal analysis of the isolated CTCs, and…
- Trial name
- NCT07186855
- Testing
- Blood Sample Collection for CTC Detection
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV
Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer
The purpose of this study is to determine whether combining ganetespib (STA-9090) with docetaxel is more effective than docetaxel alone in the treatment of subjects with advanced non-small cell lung cancer.
- Conditions
- Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Metastatic
- Trial name
- GALAXY (NCT01348126)
- Testing
- Docetaxel, Combination of ganetespib and docetaxel
- Where
- 53 sites in United States, Belgium and 11 more
- Volunteers
- 385 people
- Sponsor
- Synta Pharmaceuticals Corp.
Advanced Cancer
Suberoylanilide Hydroxamic Acid in Advanced Solid Tumors
The purpose of this investigational study is to determine the safety and tolerability of oral suberoylanilide hydroxamic acid when administered in combination with standard doses of pemetrexed and cisplatin for the treatment of…
- Trial name
- NCT00106626
- Testing
- vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in combination with Pemetrexed and Cisplatin
- Volunteers
- 52 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.